FDA puts clinical hold on cancer drug study

Nurix Therapeutics, a drugmaker based in San Francisco, said the FDA has placed a partial clinical hold on its phase 1 trial for an experimental drug for lymphoma and leukemia. 

The partial hold comes after Nurix told the agency of its plan to "transition to an improved manufacturing process," the drugmaker said in a Nov. 1 news release. 

The study is testing Nurix's drug NX-2127 and involves 160 adult participants with relapsed or refractory B-cell malignancies, according to clinicaltrials.gov. Patients already receiving treatment will continue their regimens, but new enrollment is currently paused with the clinical hold.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars